Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today, we’re looking at FDA Commissioner Marty Makary’s new voucher program, which continues to draw concern from both inside and outside the agency.
The need-to-know this morning
- There are pharma earnings, and then there are Eli Lilly earnings. The latter delivered the season’s standout performance, highlighted by 2026 financial guidance that hurdled over Street consensus. Analysts noted that Lilly’s strong forecast assuages concerns about pricing headwinds negatively impacting growth in the company’s juggernaut obesity franchise, and stands in stark contrast to yesterday’s sales warning from Novo Nordisk.
- Novartis, GSK and Abbvie reported earnings, too.
Trump officials blocked effort to speed review of Compass’ psychedelic treatment
The FDA last year wanted to expedite the review of Compass Pathways’ psilocybin treatment for severe depression as part of a new voucher program, but Trump administration officials vetoed the plan, STAT has learned.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply